Skip to main content

Advertisement

SpringerLink
Log in

Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective: Increased osteoprotegerin (OPG) levels are associated with increased cardiovascular risk and decreased bone resorption. Pioglitazone treatment reduces the inflammatory state but may decrease bone mineral density (BMD). OPG levels during pioglitazone treatment have not previously been evaluated in polycystic ovary syndrome (PCOS). Research design and methods: Plasma OPG levels were measured in 30 PCOS patients before and after randomized treatment with 30 mg pioglitazone/placebo for 16 weeks. Fourteen age- and body mass index-matched healthy women were included as controls. Clinical and hormonal evaluations and whole body dual-energy X-ray absorptiometry scans were performed in all participants. Results: OPG levels were comparable in PCOS patients [12.0 (10.5–14.6) ng/ml] and controls [12.9 (11.7–14.9) ng/ml]. In PCOS patients (no.=30), OPG levels were positively associated with testosterone (r=0.43), PRL (r=0.47), Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (r=0.43), and hip BMD, whereas inverse associations were found between OPG levels and triglyceride (r=−0.49) and free fatty acid levels during euglycemic clamps (r=−0.38), all p<0.05. Pioglitazone treatment significantly decreased inflammatory markers, insulin sensitivity, and BMD without affecting OPG levels. Conclusions: OPG levels were comparable in PCOS patients and controls and unchanged during insulin sensitizing treatment with pioglitazone. OPG levels were associated with BMD in PCOS. Future studies need to evaluate OPG as a marker of cardiovascular disease in PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 1: 19–25.

  2. Salley KE, Wickham EP, Cheang KI, et al. Position Statement: Glucose Intolerance in Polycystic Ovary Syndrome. A Position Statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007, 12: 4546–56.

    Google Scholar 

  3. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002, 9: 1135–43.

    Google Scholar 

  4. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 9468: 1415–28.

    Google Scholar 

  5. Douchi T, Ijuin H, Nakamura S, et al. Body fat distribution in women with polycystic ovary syndrome. Obstet Gynecol 1995, 4 Pt 1: 516–9.

    Google Scholar 

  6. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001, 6: 1255–60.

    Google Scholar 

  7. Fauser BC, Bouchard P. Uncertainty remains in women with PCOS regarding the increased incidence of cardiovascular disease later in life, despite the indisputable presence of multiple cardiovascular risk factors at a young age. J Clin Endocrinol Metab 2011, 12: 3675–7.

    Google Scholar 

  8. Dagogo-Jack S, al Ali N, Qurttom M. Augmentation of bone mineral density in hirsute women. J Clin Endocrinol Metab 1997, 9: 2821–5.

    Google Scholar 

  9. Castelo-Branco C, Pons F, Martinez de Osaba MJ, Garrido J, Fortuny A. Menstrual history as a determinant of current bone density in young hirsute women. Metabolism 1996, 4: 515–8.

    Google Scholar 

  10. Glintborg D, Andersen M, Hagen C, Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol (Oxf) 2005, 6: 683–91.

    Google Scholar 

  11. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril 1999, 1: 21–5.

    Google Scholar 

  12. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet Med 2000, 2: 124–9.

    Google Scholar 

  13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 2: 165–76.

    Google Scholar 

  14. Nybo M, Rasmussen LM. Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. Atherosclerosis 2008, 1: 33–5.

    Google Scholar 

  15. D’Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009, 32(Suppl 4): 6–9.

    PubMed  Google Scholar 

  16. Davenport C, Ashley DT, O’sullivan EP, et al. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. J Hypertens 2011, 12: 2469–75.

    Google Scholar 

  17. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010, 19: 2049–61.

    Google Scholar 

  18. Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011, 4: 638–44.

    Google Scholar 

  19. Escobar-Morreale HF, Botella-Carretero JI, Martinez-Garcia MA, et al. Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur J Endocrinol 2008, 3: 225–32.

    Google Scholar 

  20. Pepene CE, Ilie IR, Marian I, Duncea I. Circulating osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. Eur J Endocrinol 2011, 1: 61–8.

    Google Scholar 

  21. Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril 2006, 2: 385–97.

    Google Scholar 

  22. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003, 3: CD003053.

    PubMed  Google Scholar 

  23. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 3: 797–802.

    Google Scholar 

  24. Glintborg D, Andersen M. Thiazolinedione treatment in polycystic ovary syndrome. Gynecol Endocrinol 2010, 26: 791–803.

    PubMed  Google Scholar 

  25. Glintborg D, Frystyk J, Hojlund K, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 2: 165–74.

    Google Scholar 

  26. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008, 5: 1696–701.

    Google Scholar 

  27. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005, 24: 2578–88.

    Google Scholar 

  28. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 3: 269–74.

    Google Scholar 

  29. Hother-Nielsen O, Henriksen JE, Staehr P, Beck-Nielsen H. Labelled glucose infusate technique in clamp studies. Is precise matching of glucose specific activity important? Endocrinol Metab 1995, 2: 275–87.

    Google Scholar 

  30. Nybo M, Preil SR, Juhl HF, et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. Basic Clin Pharmacol Toxicol 2011, 6: 481–5.

    Google Scholar 

  31. Lykkesfeldt G, Bennett P, Lykkesfeldt AE, et al. Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis. Clin Endocrinol (Oxf) 1985, 4: 385–93.

    Google Scholar 

  32. Nybo M, Rasmussen LM. The capability of plasma osteoprotegerin asa predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 2008, 5: 603–8.

    Google Scholar 

  33. Geusens P. Emerging treatments for postmenopausal osteoporosis — focus on denosumab. Clin Interv Aging 2009, 4: 241–50.

    PubMed Central  PubMed  Google Scholar 

  34. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 2: 456–88.

    Google Scholar 

  35. Witasp A, Carrero JJ, Hammarqvist F, et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest 2011, 5: 498–506.

    Google Scholar 

  36. Harslof T, Husted LB, Carstens M, et al. The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture. Horm Metab Res 2011, 7: 477–82.

    Google Scholar 

  37. Gannage-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008, 3: 353–9.

    Google Scholar 

  38. Frederiksen L, Hojlund K, Hougaard DM, et al. Testosterone therapy decreased subcutaneous fat and adiponectin in ageing men. Eur J Endocrinol 2012, 3: 469–76.

    Google Scholar 

  39. Frederiksen L, Hojlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012, 1: 145–56.

    Google Scholar 

  40. Frederiksen L, Nielsen TL, Wraae K, et al. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 2009, 10: 4010–5.

    Google Scholar 

  41. Jensky NE, Criqui MH, Wright CM, et al. The association between abdominal body composition and vascular calcification. Obesity (Silver Spring) 2011, 12: 2418–24.

    Google Scholar 

  42. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007, 5: 1389–95.

    Google Scholar 

  43. Kenny AM, Kleppinger A, Annis K, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010, 6: 1134–43.

    Google Scholar 

  44. Turner A, Chen TC, Barber TW, et al. Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects. Clin Endocrinol (Oxf) 2004, 5: 560–6.

    Google Scholar 

  45. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 6: 2784–91.

    Google Scholar 

  46. Boden G, Cheung P, Mozzoli M, Fried SK. Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003, 6: 753–9.

    Google Scholar 

  47. Glintborg D, Andersen M, Richelsen B, Bruun JM. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf) 2009, 5: 652–8.

    Google Scholar 

  48. Park JS, Cho MH, Nam JS, et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol 2011, 1: 69–74.

    Google Scholar 

  49. Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem 2009, 4: 677–85.

    Google Scholar 

  50. Seriwatanachai D, Thongchote K, Charoenphandhu N, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008, 3: 535–46.

    Google Scholar 

  51. van Zaane B, Reuwer AQ, Buller HR, et al. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences? Semin Thromb Hemost 2009, 5: 478–87.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Odense University Hospital, Kløvervænget 6, 3rd floor, DK-5000, Odense C, Denmark

    D. Glintborg, A. P. Hermann & M. Andersen

  2. Department of Biochemistry, Odense University Hospital, Odense, Denmark

    L. M. Rasmussen

Authors
  1. D. Glintborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. P. Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. M. Rasmussen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Glintborg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glintborg, D., Hermann, A.P., Rasmussen, L.M. et al. Plasma osteoprotegerin is associated with testosterone levels but unaffected by pioglitazone treatment in patients with polycystic ovary syndrome. J Endocrinol Invest 36, 460–465 (2013). https://doi.org/10.3275/8767

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8767

Key-words

Search

Navigation